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Ερευνητικό άρθρο
ABSTRACT. Immune assays were taken into consideration to diagnose and quantify metabolites such as antigen 
and antibody. Enzyme-Linked Immunosorbent Assays (ELISAs), which are used to detect antigens and antibodies, 
generated several periods of infectious and vaccination conditions. There is an extensive range of commercial infec-
tious disease ELISA kits useful for the detection of human and animal IgG, IgA, IgM antibodies and microorganism 
antigens. Anthrax is one of the serious infectious diseases caused by rod-shaped, gram-positive bacteria known as 
Bacillus anthracis. Subunit or attenuated vaccines applied against anthrax disease increase the antibody against the 
Protective Antigen (PA) which has a critical role as a toxin of B. anthracis. Herein, the ELISA was developed using 
PA domain 4 and anthrax Lethal Factor to detect IgG antibody in serum. Besides, the level of anti-LF antibodies were 
determined as a complementary test to measure variance in antibody titers associated with vaccination or infection that 
leads to detection of anthrax in livestock. The results show that we developed high-quality ELISA kit that can be used 
to test immunogenicity of vaccines and infections in mice. We tried to develop the Anti- PA4 ELISA kit and conduct 
the validation studies to evaluate the fluctuation level of the antibody in the anthrax vaccine and distinction between 
disease and vaccination in mice.
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INTRODUCTION
Enzyme-linked Immunosorbent Assays (ELISAs) as an immune assays approach are applied to 
detect antigens and antibodies throughout the infec-
tious and vaccination situation. Nowadays, a broad 
range of commercial ELISA kits is being utilized to 
detect human and animal IgG, IgA, IgM antibodies 
and microorganism antigens. Since its discovery 80 
years ago, the live attenuated Sterne strain (34F2) of 
B. anthracis has been successfully used as the pre-
dominant method to immunize livestock against an-
thrax, leading to the control of several positive cases 
of anthrax in different species (Tadayon et al., 2016). 
The mechanism employed by such vaccines is to trig-
ger the immune system against the protective antigen 
(PA) of the B. anthracis (Dumas et al., 2017). Anthrax 
toxin is composed of protective antigen (PA), lethal 
factor (LF) and edema factor (EF). All of which play 
a significant role in boosting the immune system’s re-
sponse to such vaccines; however, the PA (among the 
three component PA, LF and EF) is the most effec-
tive factor in increasing the immunogenicity in B. an-
thracis toxin (Zai et al., 2016). Although the existing 
vaccines such as AVA are safe and effective, there has 
been a surge in the need for anthrax vaccines due to 
the increased terroristic attacks in the recent decades. 
Furthermore, the prevalence of such bacteria among 
humans has highlighted the necessity of research and 
developing methods of producing subunit vaccines 
(Malik et al., 2018). PA is one of the most import-
ant antigens in the anthrax which is used in the de-
sign of vaccines and several commercial diagnostic 
kits. It plays a key role in the pathogenesis of B. an-
thracis, and if the antibody against PA is produced, it 
can prevent the binding of PA to the cell surface, and 
eventually the function of B. anthracis toxin will be 
impaired{Male, 2017 #109} (Goldsteinet al., 2017). 
The anthrax PA is a four-domain protein that each part 
plays a specific role (Male et al., 2017). The fourth do-
main maintains the structure and binding to the host 
receptor Capillary morphogenesis protein 2 (CMG2) 
which leads PA to bind to the cell. So the PA domain 4 
(PA4) has a critical role in the function of PA and the 
toxin of B. anthracis (Mamillapalli et al., 2017). Sub-
unit vaccines or attenuated vaccines applied against 
anthrax disease increase the immune systems’ anti-
body against the PA. Therefore, the cornerstone of a 
vaccine showing its protection and efficacy in curbing 
the disease is the power of antibody applied against 
the PA (Sim et al., 2017). {Sim, 2017 #113} 
Testing the potency of anthrax vaccine entails us-
ing a virulent strain of B. anthracis so that the real 
immunization of the vaccine would be determined 
(Moazeni et al., 2007). Conducting bioassay and le-
thal challenge on laboratory animals with the viru-
lent strain entails the use of specialized containment 
equipment including class-3 facilities, proper envi-
ronment and special laboratory tools. Such facilities 
are not available everywhere (Milleret al., 2012). On 
the other hand, testing the immunization of a vaccine 
in field and clinical studies entails the adoption of a 
safe and simple method (Ionin et al., 2013). The exist-
ing ELISA kits measure the practicality of antibodies 
against PA. The amount of antibody produced against 
PA shows the stimulated cases, (human or animal) 
possibility of exposure to the microorganism or the 
vaccination (Laws et al., 2016). However, determina-
tion of the subjects’ exposure to the microbe or vac-
cine is not possible with the available ELISA kits. 
Studies show that the most specific antibody 
against the B. anthracis is the antibody produced 
against the PA4. That is because the generated an-
ti-PA4 prevents PA’s binding to the receptors in the 
cell surface and consequently prohibits the LF and 
EF from entering the cell and causing the disease. 
Therefore, measuring the titer of anti-PA4 following 
the injection of PA4 to mice can provide a safe and 
simple method to show the potency of such vaccines 
(Williamson et al, 2015). On the other hand, the use 
of the PA4 in the ELISA kit design can be indicative 
of an effective immune response against the disease 
as compared to other commercial types.
The present study tries to use the new recombinant 
antigen PA4 to survey the pattern of humoral immu-
nity responses kinetically. It is done after the injection 
of AVA, Razi anthrax vaccine and PA4 antigen with 
aluminum hydroxide adjuvant. In order to differen-
tiate the infection caused by the B. anthracis and the 
immunity obtained from injecting several anthrax 
vaccine, virulent strain B. anthracis (17JB) with a sub 
lethal dose was used to survey the rise of produced 
antibody against PA4 and LF. The Anti-PA4 ELISA 
was developed and the validation studies were con-
ducted to evaluate the antibody titer in the anthrax 
vaccine in mice. The validation purpose of this ap-
proach is to show that such method suits our study. 
All of the needed instructions have been followed to 
validate the study based on the international Confer-
ence of harmonization (ICH). (Pombo et al., 2004).
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MATERIALS AND METHODS
Antigens and Vaccines
The new recombinant PA4 and the LF antigens 
were supplied from Razi Vaccine and Serum Research 
Institute’s Immunology Department (Karaj, Iran) and 
kept at the temperature of -70 °c. The AVA vaccine 
was supplied from Biothrax Company. The Razi an-
thrax vaccine, which is a B. anthracis live spore vac-
cine, and the B. anthracis strain 17JB were supplied 
from Razi Vaccine and Serum Research Institute. 
Reference Serum
The domestic reference serum dubbed ‘Pool’ used 
in the research as the PA4 antigen (25 µg) was mixed 
with the aluminum hydroxide adjuvant 2.5% V/V, 
which was diluted 1/10 with PBS, and 0.25mL of 
the mixture was injected subcutaneously to ten mice 
Balb/c in the timespan of thirty days. The blood sam-
pling was conducted in the weeks 1, 2, 4, 6, 8, and 
10 and the serum was collected afterwards. The se-
rum attained from 3 mice with the most OD (>2.5) 
during those dates was selected and mixed together. 
The serum pool of its antibody was conventionally set 
as 800 EU/mL. It was divided into 0.2 mL micro tubes 
and kept at the temperature of -70 °C (Pombo et al., 
2004).
Samples
Experimental Balb/C mice were allocated into five 
groups, each containing ten animals. Mice of the first 
three groups were treated in the days 1 and 15 with 
0.25mL AVA vaccine, 0.25mL of The Razi Anthrax 
vaccine and 25µg PA4 antigen with aluminum hydrox-
ide adjuvant, respectively. The fourth group contains 
the virulent strain of B. anthracis (17JB) in which 150 
B. anthracis live spore was injected subcutaneously; 
the sampling was carried out on third and fifth weeks. 
For the last group, Normal Mouse Serum (NMS) was 
applied to be used as a negative control (Xiang et al., 
1994). All serums kept at the temperature of -70 °C. 
All experimental protocols were conducted according 
to the principles described in guidelines for care and 
use of laboratory animals and approved by the Re-
search and Ethics Committee of Babol University of 
Medical Sciences (MUBABOL.REC.1395.175).
ELISA for anti-PA4 and anti-LF antibody 
measurement
A checkerboard titration was carried out to settle 
the optimum antigen concentration and conjugation 
was diluted by blocking buffer just before being used 
in the ELISA. Antigen concentrations considered in 
the study included 200 ng/well of PA4 and 100 ng/
well LF in 0.05 M Carbonate-Bicarbonate, and pH 
9.6 that were coated on 96 well ELISA plates (Jet 
bio, Canada) and incubated overnight for 24 h at 4◦C 
(amount of proteins were determined by Bradford as-
say). Plates were washed once with phosphate buff-
ered saline (PBS) and then they were blocked with 
200 μL/well of 3% skimmed milk (Sigma) for 24 h at 
4◦C. After washing once with PBS, the plates were in-
cubated with 100 μl/well controls and test samples at 
a dilution of 1/80 in the dilution buffer (3% skimmed 
milk) for 2 h at 37◦C. Each serum sample was tested 
in triplicate. The wells were again washed for four 
times with PBS and incubated with 100 μL/well An-
ti-mouse IgG HRP (Sigma USA) diluted to 1:40,000 
in the dilution buffer and incubated at 37◦C for 2h. 
Finally, washed for five times with PBS, unbound an-
tibodies were removed and the bound antibodies were 
detected virtually after 15-20 minutes in the dark us-
ing 100μl of 3,3’,5,5’-tetramethylbenzidine (TMB), 
containing hydrogen peroxide (Sigma) as the sub-
strate along with H2O2. The reaction was stopped by 
adding 50µl of HCL 5.8% and absorbance was read 
in wavelength 450 nm against 630 nm second filters 
in an ELISA reader (Stat Fax. USA) and ELISA value 
was obtained (Ndumnego OC et al., 2013). All wash-
ing steps were carried out with micro plate washer 
(STAT FAX, USA).
Linearity
A total of seven serum samples of varying anti-
body concentrations, S1 through S7, were used for the 
assessment of linearity. The S1 is the domestic refer-
ence serum ‘Pool’. Of the S1, the samples S2 through 
S7 were attained with dilutions of 1/2 to 1/64. The 
NMS was used for the dilution of all samples. All 
samples, S1 to S7, were put in three different plates 
in triplicate. As per protocol, the amount of anti-PA4 
in all samples was obtained based on optical densi-
ty (OD). The curve linearity was obtained from the 
analysis of the empirically observed log10 amount of 
antibody in the samples and finally was reported as 
EU/mL. Through the attained results, the P-value, the 
correlation coefficient, the y-intercept and the slope 
of the regression line were calculated (Semenova et 
al., 2017).
 Accuracy
To perform the accuracy test, the samples S1, S3, 
S5 and S7 were used. In this test, coating was carried 
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out according to paragraph 2.5; the amount of an-
ti-PA4 was assessed based on OD and reported as EU/
mL. The accuracy is expressed as percent recovery 
and is calculated with the following formula: Mean 
estimated unitage per mL / assigned unitage per mL 
× 100.
The calculated concentration from each sample 
shows the average geometrical estimation based on 
the S1 which is corrected by the dilution of each sam-
ple (Pombo et al., 2004). 
Precision
The assessment of repeatability (Intra-plate, In-
ter-plate, and Intra-day) and intermediate precision 
between the days and analysts was conducted accord-
ing to the definitions ICH. Precision was determined 
using three samples namely S1, S3 and S5 which were 
in accordance with linearity tests. In this stage, coat-
ing was also conducted according to paragraph 2.5. 
Based on the protocol, the amount of anti-PA4 was 
measured independently by two analysts in three con-
secutive days and then the average OD was assessed 
for each sample. Finally, the results were expressed in 
EU/mL and the results of OD for each sample were 
calculated by %CV (SD/mean×100) (Semenova et al., 
2012).
Quantification Limit (LOQ)
To perform this test, three samples namely S5, S6 
and S7, which indicated a low concentration of the 
antibody, were used. Coating was conducted accord-
ing to paragraph 2.5. According to the protocol, the 
amount of anti-PA4 was measured based on OD in 
three non-consecutive days within an eight-day peri-
od. The average OD was calculated for each sample 
and at the end, the antibody was reported by EU/mL 
for each sample. The results of OD were assessed by 
%CV (SD/mean×100) (Ghosh et al., 2015). 
Detection Limit (LOD)
Detection limit (LOD) was obtained using two 
NMS serums with the dilution of 1/80 and each sam-
ple was divided into two different plates in triplicate. 
Anti-PA4 was measured based on OD according to 
ELISA protocol in five non-consecutive days in a 
two-week period. The LOD was estimated by inter-
polating the mean of all 68 OD values, plus standard 
deviations. The LOD was calculated by the following 
formula: Mean (OD) + 3SD; then, it was reported in 
EU/mL (Ghosh et al., 2015). 
Specificity
To perform this test, besides the Pool and NMS se-
rums, other serums namely Foot-and-mouth Disease 
(FMD), Pasteurella (PAS), Agalactia (AG) and diph-
theria pertussis (whooping cough) and tetanus (DTP), 
which were obtained in previous studies, were used. 
Three different dilutions (1/80, 1/160 and 1/320) were 
prepared from each sample using the NMS serum. 
The serums were put in two separate plates and ELI-
SA value was obtained. Only one dilution (1/80) was 
used for NMS.
Competitive Inhibition ELISA
To determine the specificity of the measurements 
performed by ELISA, competitive inhibition ELISA 
(CI-ELISA) has been developed based on the qual-
ified anti-PA4 IgG ELISA. The CI-ELISA was per-
formed by using following modifications of the stan-
dard ELISA procedure. 96-well polystyrene plates 
(Jet bio, Canada) were coated at 4°C for 24h with 200 
ng/well PA4 antigen in 0.05 M carbonate-bicarbon-
ate buffer (pH 9.6) per well. The plate was washed 
once with phosphate buffered saline (PBS). After the 
blocking with 200 μl skimmed milk %3 at 4◦C for 24h 
and washing once, 100 μl of 1:80 dilution serum and 
780 pg to 800ng of PA4 were added and incubated at 
37°C for 2h. limiting concentration was determined 
empirically by the titration of anti-PA4 in standard 
ELISA. The wells were washed four times with PBS 
and incubated with HRP anti-mouse immunoglobulin 
G (Sigma, USA.) at 37ºC for 2h. Finally, wells were 
washed five times with PBS, 100µ of substrate buffer 
containing TMB per mL was added, and the mixture 
was incubated for 15-20 min. In the follow-up step 
of ELISA, reactions were stopped by adding 50µl of 
Hcl5.8%, and the optical density (OD) at 450 nm and 
630 was determined and ELISA value was obtained. 
(Ndumnego et al., 2013; Mitic et al., 2016).
Comparing the amount of antibody against PA4 
and LF antigens in the vaccinated mice with the 
mice injected with virulent strains of B. anthracis
The two antigens PA4 (200ng) and LF (100ng) 
were coated in two separate plates to compare the an-
tibody against the LF and PA4 in sera of the vaccinat-
ed mice and the mice injected with virulent strains of 
B. anthracis. Tests were performed in duplicate.
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 07/06/2020 15:49:51 |
J HELLENIC VET MED SOC 2020, 71(1)
ΠΕΚΕ 2020, 71(1)
1939H. R. NOURI, H. RAZZAZ, M. TAGHDIRI, K. TADAYON, S. R. BANIHASHEMI
RESULTS
Performance Characteristics of the Anti-PA4 IgG 
ELISA
The assessment of Antibody development pattern 
proved that all vaccinated mice had anti-PA4 as deter-
mined by ELISA, with ELISA values which gradually 
increased until week 4, then slowly declined (Figure. 
1). Antibodies were detectable by 2 to 4 weeks after 
vaccination (Figure. 1). Sera from the NMS did not 
develop titers by ELISA (Figure.1).
Fig. 1. Antibody levels in vaccinated and NMS mice as deter-
mined by ELSA. Open symbols indicate vaccinated mice, and 
solid symbols indicate NMS mice. Vaccinated mice were inoc-
ulated with PA4 antigen plus adjuvants, Razi Vaccine and AVA 
subcutaneously.
Linearity 
After calculating the log10, the obtained OD val-
ues from all of the samples, S1 through S7, showed 
that the curve in the range 14-892 EU/mL was com-
pletely linear and the values showed to be as follows: 
r2 = 0.9628, P- value < 0.005 and Y= ax + b ( Y= 
0.9601x+b) (Figure.2).
Fig. 2. Linearity curve. EU/mL of seven dilutions of S sera (the 
pool as domestic reference serum) are plotted against varied dilu-
tion (1:2, 1:4, 1:8, 1:16, 1:32, and 1:64). Each point represents the 
estimated EU / mL of each unit that was tested three times.
Accuracy
The accuracy results in Table-1 are stated in the 
form of percent recovery. To perform the test, the 
range between 16-1000 EU/mL was studied and the 
percent recovery came out to be between 90-117%. 
The resulted percent fits the validation criteria accord-
ing to Table 2.
Table 1. Accuracy assessment. The accuracy results are stated in the form of percent recovery.
Replicates Target sample (EU/mL)
S1 (1000) S3 (250) S5 (62.5) S7 (16)
% % % %
Recovery Recovery Recovery Recovery 
Plate 1 1 94.3 100 82 110
 2 95 101 84 117
 3 112 102 93 120
Plate 2 1 104 100 90 130
 2 110 108 92 120
 3 108 110 90 114
 
Plate 3 1 93 103 90 130
 2 103 100 103 100
 3 102 103 89 110
Mean 102.36 103 90.33 116.77 
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Table 2 .Acceptance criteria and characteristics of the anti-PA4 mouse ELISA. To perform the test, the range between 16-1000 EU/
mL was studied and the percent recovery came out to be between 90-117%.
Assay characteristic Acceptance criteria Results
Prescision-repeatability
  Intra-plate
  Inter-plate
  Intra-day
Intermediate prescision
  Days
  Analysts
Accuracy
Limit of detection (LOD)
Limit of quantitation (LOQ)
Linearity
  %CV < 20
 %CV ≤ 25
  %CV ≤ 30
  80 - 120%
  Recovery
-
-
- 
%CV ≤ 13.7
%CV ≤ 15
%CV ≤ 12
%CV ≤ 18
%CV ≤ 7
90 - 117%
Recovery
7 EU/mL
14 EU/mL
Working range:
27 - 892 EU/mL 
r2 = 0.96
Table 3. Specificity. To perform this test, besides the Pool and NMS serums, other serums namely Foot-and-mouth Disease (FMD), 
Pasteurella (PAS), Agalactia (AG) and diphtheria pertussis (whooping cough) and tetanus (DTP) were used.
Sample Pool Dilution in well Elisa valuesPlate 1 Plate 2
 1:80 99.192 92.419
 1:160 77.943 80.846
           1:320 67.096 61.935
FDM  1:80 1.251 0
 1:160 0 1.221
 1:320 1.114 0
AG  1:80 1.212 0
 1:160 1.231 1.212
 1:320 0 0
PAS  1:80 1.123 1.232
 1:160 0 1.253
 1:320 0 0
DTP  1:80 1.232 1.235
 1:160 1.321 1.123
 1:320 0 1.232
  1:80 0* 0*
*Mean of four Elisa values
Precision, LOD, LOQ
In order to survey the precision, the range be-
tween 55-850 EU/mL was calculated by the formu-
la: (S1=850EU/mL, S3=214EU/mL, S5=55EU/mL). 
For the assessment of precision-repeatability, all OD 
values were calculated based on %CV and the values 
obtained as %CV≤ 14 in the intra-plate, %CV≤15 in 
inter-plate and %CV≤ 12 in the inter-day. All of the 
results fit the validation criteria which is mentioned 
in Table 2. To assess the Intermediate-precision, all 
of the OD values were also calculated based on %CV, 
with the values standing at Days %CV≤ 18 and Ana-
lyst %CV≤ 7, all of which fit the validation criteria. To 
determine the LOD, we followed the 2.12 paragraph 
which led to the assessment of 7 EU/mL. The assay 
of LOQ was conducted between 14-58 EU/mL (S5= 
58EU/mL, S6= 27EU/mL, S7= 14EU/mL). All of the 
OD values were calculated based on %CV, showing 
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the value of %CV≤ 17 in all Inter-plate, Intra-plate 
and Intra-day precision, which fits the validation cri-
teria. But, in Inter-day, the value of S7=14EU/mL 
%CV≤ 26 was obtained, which is not compatible with 
the criteria. Therefore, although the curve linearity in 
the 14-895 EU/mL is linear, the lowest amount of an-
ti-PA4 which could be measured by ELISA method is 
shown to be 27 EU/mL.
Specificity
In Table-3, the increase of ELISA value was only 
observed in the Pool sample in all three dilutions of 
1/80, 1/160, and 1/320 whilst other samples did not 
reveal any increase. So, the results of this table show 
that the anti-PA4 is completely specific and does not 
have any cross-reaction with other antigens. (Table 3)
Comparative analysis of anti-PA4 IgG
A competitive inhibition ELISA (CI-ELISA) was 
developed based on the qualified anti-PA4 ELISA. 
The aim of the CI-ELISA was to increase the speci-
ficity of the ELISA by reducing the incidence of false 
positives.
The PA4 was used to prove the ability of binding 
the antibody to antigen coated to the plate. This dia-
gram shows that Anti-PA4 reacts with PA4 in a liq-
uid-phase, and the PA4 antigen existing in the serum 
competes with the PA4 antigen coated in the plate on 
binding with the antibody; this leads to the reduction 
of ELISA value.
That means, the lower the PA4 in the serum, the 
more ELISA value will be, and the more it becomes, 
the less the ELISA value will get. The results of the 
study shown in Figure. 3 prove this claim.
Fig. 3. A competitive inhibition ELISA (CI-ELISA). In the se-
rum sample with the lower amount of PA4 antigen (0.78 ng) and 
the serum sample with the greater amount of PA4 antigen than 
the rest of the samples (800 ng), the highest ELISA value and the 
lowest ELISA value were observed respectively.
Comparing the amount of antibody against PA4 
and LF in the vaccinated mice and the mice 
injected with virulent strain
We show that groups of AVA and Razi anthrax 
vaccine serums contain antibodies against the PA4 
and LF but the Pool serum only has anti-PA4 whilst 
the NMS and B. anthracis 17JB groups lack such an-
tibodies. Therefore, the results indicate that the mice 
having received the anthrax vaccine produce the an-
tibody against the PA4 and LF after the third week 
(Table 4). Those injected with the strain 17JB only 
produce the detectible antibodies against LF after the 
fifth week. (Table 5),
Table 4. Comparing the amount of antibody against PA4 and LF in vaccine groups. A standard ELISA was performed for Anthrax 
vaccine adsorbed (AVA), Razi anthrax vaccine, Pool sera, NMS sera against anti PA4 and anti LF antigens. The ELISA value was 
significantly different between them.
Sample Dilution in well Elisa values
PA4 coating LF coating
AVA 1:80 25.403 21.37
Anthrax vaccine 1:80 28.225 24.193
RAZI
Pool 1:80 97.983 0
NMS 1:80 0* 1.123*
*Mean of four Elisa values
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Table 5. Comparing the amount of antibody against PA4 and LF in 17JB group. In order to detect antibody against PA4 and LF 
antigens, standard ELISA was performed for two groups of 17JB and NMS in the 3th and 5th weeks after the injection of strain 17JB. 
The Elisa value (after 5 weeks) was significantly different between them.
Sample Dilution in well Elisa value after 3 weeks Elisa values after 5 weeks
PA4 coating LF coating PA4 coating LF coating
17JB 1:80 0 1.209 1.151 17.195
NMS 1:80 0* 1.123* 1.021* 1.054* 
*Mean of four Elisa values
DISCUSSION
The research conducted on the humoral immune 
response of the anthrax vaccines show that the role 
of anti-PA is the main factor of the vaccine’s efficacy 
(Chen L, 2014). Therefore, future studies can look at 
this parameter more specifically to prove the immu-
nity effects of the anthrax vaccine (Reuveny et al., 
2001). The common ELISA kits have been monitored 
by full structure of PA. However, in an examination, 
the antibody measured is based solely on an important 
domain of PA (named PA4). The anti-PA4 can be an 
effective factor in the monitoring of the humoral im-
mune response of all three existing vaccines against 
the B. anthracis (Flick-Smith et al., 2002).
To obtain the WHO and FDA license for manu-
facturing such vaccines for humans and animals, re-
searchers need to survey the humoral immunity re-
sponses or anti-PA. In this study, we have developed 
an ELISA method detecting anti-PA4 (Weiss et al., 
2007). All of the parameters have been assessed to 
validate the mentioned methods, and the results of the 
study show their validity for studying humoral immu-
nity responses. As the study indicates, the coated PA4 
antigen in the well plates did not cause any unspecific 
reaction against other livestock diseases as mentioned 
in Table 3. Moreover, through other validation tests, 
this test can be conducted in all laboratories by dif-
ferent researchers and bear the most accurate results. 
According to Table 4, using this method, the produced 
antibodies following the injection of anthrax vaccines 
in mice can be measured and the kinetic answers for 
future studies can be found. Although the most sen-
sitive animal for such processes is guinea pig, using 
mice has several other advantages namely the con-
venience of testing and their abundance which make 
researchers forgo some of the disadvantages (Pombo 
et al., 2004). 
One of the significant points in the application of 
this method, according to table 4 and 5, is that we 
created a model of anthrax disease in the mice via 
injecting the 17JB strain and measured the produced 
antibody against PA4 and LF, then compared it with 
the vaccinated groups. The positive control shows the 
increase in the antibody against PA4 and LF in the 
vaccinated groups despite what was shown in the dis-
ease groups.
Previous studies show that the amount of anti-PA 
in animals suffering from anthrax in the form of a skin 
disease has been increased. Therefore, the method, in 
which Anti-PA4 did not increase in comparison with 
the vaccinated group, can be a good option for screen-
ing cases suspected with infections from the vaccinat-
ed ones (Baillie LW et al., 2010; Ingram et al., 2010). 
The increase of anti-PA in the disease groups could 
be due to the presence of antibody against other PA’s 
domains, which needs further studies. In addition, an-
other reason for such diseases can be lack of PA in a 
pathogenic form (Ingram et al., 2010).
Although the performed studies represented that 
the levels of antibody increased against LF in the fifth 
week and this can be the point of difference between 
negative control and 17JB groups, the disadvantage 
of the described method is that it is not capable of dis-
tinguishing between the negative control group and 
the 17JB group during the first three weeks.
CONCLUSION
Through the validation tests carried out on this 
ELISA method, we showed that the detection range 
of the anti-PA4 can be 27- 892 EU/mL. We also be-
lieve that this ELISA method can be adopted in other 
laboratories in order to assess the immunity responses 
and differentiation of disease from vaccination after 
the first month. At the end, we can use this method as 
one of the alternative potency tests. 
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